Caregen (CEO Yongji Jeong), a bio company specializing in peptides, announced on the 26th that it will participate as an emerald sponsor in the IMCAS World Congress 2026, which will be held at the Palais des Congrès in Paris, France from January 29th to 31st.
Now in its 28th year, IMCAS is the world's largest medical aesthetics conference. It attracts approximately 20,000 attendees from 136 countries, including dermatologists, plastic surgeons, and representatives from global beauty and healthcare companies. It is recognized as a key platform for sharing the latest clinical data and technological trends and forging global business partnerships.
Caregen has been participating in IMCAS for over 20 years, since the early 2000s. Through this, it has introduced new products to the global market and expanded partnerships with key buyers. This long-term participation has helped Caregen establish itself as a peptide technology company in the global medical aesthetics market.
While approximately 80 Korean companies are expected to participate in this conference, Caregen is the only domestic company to secure the highest sponsorship level, the Emerald Sponsorship. Caregen plans to operate a dedicated booth and place large advertisements along the main paths and in the main lobby to enhance brand exposure. The company will showcase key product lines, including REVOFIL and DR.CYJ hair fillers, with a focus on the design renewal and latest clinical updates for its flagship product, CG Dimono PTx.
On the first day of the event, the 29th, a Caregen-only symposium will be held under the theme of "Inside-Out Aesthetic Transformation." CEO Jeong Yong-ji will present the renewal details and clinical data of the peptide-based dermal filler CG Dimono PTx, as well as clinical data and application strategies for the oral weight management GLP-1 peptide Coglutide.
Alongside this, four global key doctors from a Mexican partner company will take the stage to share the latest clinical cases and treatment techniques utilizing peptide filler products like REVOFIL and Aquashine. Caregen's core strategy is to expand its peptide platform, rather than focusing on fillers or equipment.
Caregen plans to use its participation in IMCAS as an opportunity to strengthen its global distribution network, including in Europe, expand strategic partnerships through exchanges with key buyers, and expand its peptide platform-based pipeline.
- See more related articles
You must be logged in to post a comment.